Because researchers have made such striking progress in developing drugs to treat neuromuscular diseases, Scott Delp, Ph.D., ...
Matt’s dad, Paul, was diagnosed with Facioscapulohumeral muscular dystrophy (FSHD) about 15 years ago, when he was in his mid ...
Stanford Medicine researchers found that a smartphone could monitor patients with two types of muscular dystrophy as well as ...
FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and Devastating Mitochondrial Disease ...
Investor's Business Daily on MSN
Sarepta Crashes After Two Muscular Dystrophy Drugs Fail Confirmatory Tests
Sarepta stock crashed late Monday after the biotech company said two of its muscular dystrophy drugs failed their ...
“The approval today of KYGEVVI® (doxecitine and doxribtimine), provides real hope for patients and families living with this devastating disease,” said Angela Lek, PhD, interim Chief Research Officer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback